ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function

Igor Bado; Fotis Nikolos; Gayani Rajapaksa; Jan-Åke Gustafsson; Christoforos Thomas

doi:10.18632/oncotarget.7300

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function

Igor Bado, Fotis Nikolos, Gayani Rajapaksa, Jan-Åke Gustafsson and Christoforos Thomas _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:13599-13611. https://doi.org/10.18632/oncotarget.7300

Metrics: PDF 2078 views | HTML 2385 views | ?

Abstract

Igor Bado1, Fotis Nikolos1, Gayani Rajapaksa1, Jan-Åke Gustafsson1, Christoforos Thomas1

1Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas 77204, USA

Correspondence to:

Christoforos Thomas, e-mail: [email protected]

Keywords: estrogen receptor β, mutant p53, triple-negative breast cancer, cell invasion, p63

Received: November 05, 2015 Accepted: January 29, 2016 Published: February 10, 2016

ABSTRACT

Most (80%) of the triple-negative breast cancers (TNBCs) express mutant p53 proteins that acquire oncogenic activities including promoting metastasis. We previously showed that wild-type ERβ (ERβ1) impedes epithelial to mesenchymal transition (EMT) and decreases the invasiveness of TNBC cells. In the present study we searched for signaling pathways that ERβ1 uses to inhibit EMT and invasion in TNBC cells. We show that ERβ1 binds to and opposes the transcriptional activity of mutant p53 at the promoters of genes that regulate metastasis. p63 that transcriptionally cooperates with mutant p53 also binds to ERβ1. Downregulation of p63 represses the epithelial phenotype of ERβ1-expressing cells and alters the expression of mutant p53 target genes. These results describe a novel mechanism through which ERβ1 can disturb oncogenic signals to inhibit aggressiveness in TNBCs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7300

Publication Alerts

Research Papers:

ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function

Abstract